The immune checkpoint blockade immunotherapies anti (α)‐PD‐L1 and α‐PD‐1 have demonstrated clinical efficacy against muscle‐invasive and metastatic BC5, 6, 7, 8 and the α‐PD‐L1 antibody pembrolizumab was recently approved for treating nonmetastatic, high‐risk nonmuscle‐invasive BC.9 Here, CD274 is linked to breast cancer.